Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

iwNHL 2014 | Lymphoma microenvironment: biology and therapy (part 1/3)

John Gribben and Randy Gascoyne • 5 Sep 2014

iwNHL 2014

Non-Hodgkin Lymphoma

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumor biology and therapy. The interaction between tumor cells and non-tumor cells has been increasingly recognized to contribute to disease progression.

Investigating the treatment preferences of physicians in R/R follicular lymphoma

John Gribben • 9 Dec 2023

Axi-cel in R/R FL: an updated comparison of ZUMA-5 and the SCHOLAR-5 external control cohort

John Gribben • 9 Dec 2023

The future of CLL therapy

John Gribben • 9 Dec 2023

Novel therapies in NHL: antibody-drug conjugates

Andrew Davies et al. • 17 Oct 2023

Lymphoma Microenvironment: biology and therapy (part 2/3)

John Gribben et al. • 5 Sep 2014

Lymphoma microenvironment: biology and therapy (part 3/3)

John Gribben et al. • 5 Sep 2014

iwNHL 2015 roundtable: Using B-cell biology to inform therapy

Kieron Dunleavy et al. • 3 Oct 2015

12th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2014: Day 1 meeting highlights

John Gribben et al. • 5 Sep 2014

Related Videos

AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study

Jacopo Mariotti • 15 Apr 2024

Exciting CAR-T clinical trials in LBCL and FL

Gloria Iacoboni • 15 Apr 2024

Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing

Gloria Iacoboni • 15 Apr 2024

Using lineage tracing to define responding CAR T-cells in patients with LBCL

Zinaida Good • 9 Apr 2024